Annual SG&A
$368.40 M
+$28.90 M+8.51%
31 December 2023
Summary:
Emergent BioSolutions annual selling, general & administrative expenses is currently $368.40 million, with the most recent change of +$28.90 million (+8.51%) on 31 December 2023. During the last 3 years, it has risen by +$64.30 million (+21.14%). EBS annual SG&A is now at all-time high.EBS Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$76.60 M
-$9.30 M-10.83%
30 September 2024
Summary:
Emergent BioSolutions quarterly selling, general & administrative expenses is currently $76.60 million, with the most recent change of -$9.30 million (-10.83%) on 30 September 2024. Over the past year, it has dropped by -$9.40 million (-10.93%). EBS quarterly SG&A is now -24.38% below its all-time high of $101.30 million, reached on 31 March 2023.EBS Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$511.60 M
-$208.80 M-68.96%
30 September 2024
Summary:
Emergent BioSolutions TTM selling, general & administrative expenses is currently -$511.60 million, with the most recent change of -$208.80 million (-68.96%) on 30 September 2024. Over the past year, it has dropped by -$883.70 million (-237.49%). EBS TTM SG&A is now -114.12% below its all-time high of $372.10 million, reached on 30 September 2023.EBS TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
EBS Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +8.5% | -10.9% | -237.5% |
| 3 y3 years | +21.1% | -6.7% | -251.8% |
| 5 y5 years | +81.9% | +17.9% | -281.5% |
EBS Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +21.1% | -24.4% | at low | -114.1% | at low |
| 5 y | 5 years | at high | +81.9% | -24.4% | +17.9% | -114.1% | at low |
| alltime | all time | at high | +2649.9% | -24.4% | +586.6% | -114.1% | at low |
Emergent BioSolutions Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $76.60 M(-10.8%) | $336.90 M(-2.7%) |
| June 2024 | - | $85.90 M(+1.4%) | $346.30 M(-1.6%) |
| Mar 2024 | - | $84.70 M(-5.6%) | $351.80 M(-4.5%) |
| Dec 2023 | $368.40 M(+8.5%) | $89.70 M(+4.3%) | $368.40 M(-1.0%) |
| Sept 2023 | - | $86.00 M(-5.9%) | $372.10 M(+1.1%) |
| June 2023 | - | $91.40 M(-9.8%) | $367.90 M(+2.9%) |
| Mar 2023 | - | $101.30 M(+8.5%) | $357.60 M(+4.8%) |
| Dec 2022 | $339.50 M(-2.6%) | $93.40 M(+14.2%) | $341.10 M(-0.3%) |
| Sept 2022 | - | $81.80 M(+0.9%) | $342.20 M(-0.1%) |
| June 2022 | - | $81.10 M(-4.4%) | $342.50 M(-2.9%) |
| Mar 2022 | - | $84.80 M(-10.3%) | $352.60 M(+1.1%) |
| Dec 2021 | $348.70 M(+14.7%) | $94.50 M(+15.1%) | $348.70 M(+3.4%) |
| Sept 2021 | - | $82.10 M(-10.0%) | $337.10 M(+2.0%) |
| June 2021 | - | $91.20 M(+12.7%) | $330.50 M(+4.8%) |
| Mar 2021 | - | $80.90 M(-2.4%) | $315.30 M(+3.7%) |
| Dec 2020 | $304.10 M(+11.2%) | $82.90 M(+9.8%) | $304.10 M(+3.6%) |
| Sept 2020 | - | $75.50 M(-0.7%) | $293.40 M(+3.7%) |
| June 2020 | - | $76.00 M(+9.0%) | $282.90 M(+1.9%) |
| Mar 2020 | - | $69.70 M(-3.5%) | $277.70 M(+1.6%) |
| Dec 2019 | $273.50 M(+35.1%) | $72.20 M(+11.1%) | $273.40 M(-3.0%) |
| Sept 2019 | - | $65.00 M(-8.2%) | $281.90 M(+8.8%) |
| June 2019 | - | $70.80 M(+8.3%) | $259.00 M(+13.7%) |
| Mar 2019 | - | $65.40 M(-19.0%) | $227.70 M(+12.6%) |
| Dec 2018 | $202.50 M(+41.7%) | $80.70 M(+91.7%) | $202.30 M(+24.1%) |
| Sept 2018 | - | $42.10 M(+6.6%) | $162.98 M(+4.9%) |
| June 2018 | - | $39.50 M(-1.3%) | $155.38 M(+5.2%) |
| Mar 2018 | - | $40.00 M(-3.3%) | $147.75 M(+3.4%) |
| Dec 2017 | $142.90 M(-0.1%) | $41.38 M(+19.9%) | $142.90 M(+4.8%) |
| Sept 2017 | - | $34.50 M(+8.3%) | $136.29 M(-4.3%) |
| June 2017 | - | $31.87 M(-9.3%) | $142.48 M(-2.8%) |
| Mar 2017 | - | $35.15 M(+1.1%) | $146.53 M(+2.4%) |
| Dec 2016 | $143.10 M(+18.1%) | $34.77 M(-14.5%) | $143.10 M(-0.1%) |
| Sept 2016 | - | $40.69 M(+13.3%) | $143.21 M(+11.6%) |
| June 2016 | - | $35.92 M(+13.3%) | $128.32 M(-0.4%) |
| Mar 2016 | - | $31.71 M(-9.1%) | $128.85 M(-2.1%) |
| Dec 2015 | $121.14 M | $34.88 M(+35.2%) | $131.63 M(+15.1%) |
| Sept 2015 | - | $25.80 M(-29.2%) | $114.40 M(-3.8%) |
| June 2015 | - | $36.45 M(+5.7%) | $118.90 M(+5.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2015 | - | $34.49 M(+95.3%) | $113.00 M(+4.1%) |
| Dec 2014 | $108.59 M(+23.6%) | $17.66 M(-41.7%) | $108.59 M(-6.7%) |
| Sept 2014 | - | $30.29 M(-0.9%) | $116.33 M(+7.7%) |
| June 2014 | - | $30.55 M(+1.5%) | $108.00 M(+10.3%) |
| Mar 2014 | - | $30.09 M(+18.5%) | $97.94 M(+11.4%) |
| Dec 2013 | $87.88 M(+15.6%) | $25.40 M(+15.7%) | $87.88 M(+7.2%) |
| Sept 2013 | - | $21.95 M(+7.1%) | $81.96 M(+3.5%) |
| June 2013 | - | $20.50 M(+2.4%) | $79.16 M(+3.4%) |
| Mar 2013 | - | $20.03 M(+2.8%) | $76.55 M(+0.7%) |
| Dec 2012 | $76.02 M(+2.3%) | $19.48 M(+1.7%) | $76.02 M(+1.6%) |
| Sept 2012 | - | $19.16 M(+7.0%) | $74.80 M(+2.4%) |
| June 2012 | - | $17.89 M(-8.2%) | $73.07 M(-3.3%) |
| Mar 2012 | - | $19.49 M(+6.8%) | $75.56 M(+1.7%) |
| Dec 2011 | $74.28 M(-2.5%) | $18.25 M(+4.7%) | $74.28 M(-4.4%) |
| Sept 2011 | - | $17.43 M(-14.5%) | $77.70 M(-4.0%) |
| June 2011 | - | $20.38 M(+11.9%) | $80.96 M(+3.5%) |
| Mar 2011 | - | $18.21 M(-16.0%) | $78.22 M(+2.7%) |
| Dec 2010 | $76.20 M(+3.3%) | $21.67 M(+4.7%) | $76.20 M(+4.1%) |
| Sept 2010 | - | $20.69 M(+17.2%) | $73.20 M(+1.3%) |
| June 2010 | - | $17.65 M(+9.0%) | $72.28 M(-2.3%) |
| Mar 2010 | - | $16.19 M(-13.3%) | $74.00 M(+0.3%) |
| Dec 2009 | $73.79 M(+34.0%) | $18.67 M(-5.5%) | $73.79 M(+7.0%) |
| Sept 2009 | - | $19.77 M(+2.0%) | $68.98 M(+8.9%) |
| June 2009 | - | $19.37 M(+21.3%) | $63.33 M(+7.3%) |
| Mar 2009 | - | $15.97 M(+15.2%) | $58.99 M(+7.1%) |
| Dec 2008 | $55.08 M(-0.9%) | $13.86 M(-1.8%) | $55.08 M(-4.8%) |
| Sept 2008 | - | $14.12 M(-6.1%) | $57.88 M(-1.6%) |
| June 2008 | - | $15.04 M(+24.7%) | $58.80 M(+4.2%) |
| Mar 2008 | - | $12.06 M(-27.6%) | $56.42 M(+1.6%) |
| Dec 2007 | $55.55 M(+24.6%) | $16.67 M(+10.8%) | $55.56 M(+4.5%) |
| Sept 2007 | - | $15.04 M(+18.8%) | $53.14 M(+7.9%) |
| June 2007 | - | $12.66 M(+13.1%) | $49.26 M(+34.6%) |
| Mar 2007 | - | $11.19 M(-21.4%) | $36.60 M(+44.1%) |
| Dec 2006 | $44.60 M(+4.2%) | $14.25 M(+27.7%) | $25.41 M(+127.7%) |
| Sept 2006 | - | $11.16 M | $11.16 M |
| Dec 2005 | $42.79 M(+41.1%) | - | - |
| Dec 2004 | $30.32 M(+126.3%) | - | - |
| Dec 2002 | $13.40 M | - | - |
FAQ
- What is Emergent BioSolutions annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Emergent BioSolutions?
- What is Emergent BioSolutions annual SG&A year-on-year change?
- What is Emergent BioSolutions quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Emergent BioSolutions?
- What is Emergent BioSolutions quarterly SG&A year-on-year change?
- What is Emergent BioSolutions TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Emergent BioSolutions?
- What is Emergent BioSolutions TTM SG&A year-on-year change?
What is Emergent BioSolutions annual selling, general & administrative expenses?
The current annual SG&A of EBS is $368.40 M
What is the all time high annual SG&A for Emergent BioSolutions?
Emergent BioSolutions all-time high annual selling, general & administrative expenses is $368.40 M
What is Emergent BioSolutions annual SG&A year-on-year change?
Over the past year, EBS annual selling, general & administrative expenses has changed by +$28.90 M (+8.51%)
What is Emergent BioSolutions quarterly selling, general & administrative expenses?
The current quarterly SG&A of EBS is $76.60 M
What is the all time high quarterly SG&A for Emergent BioSolutions?
Emergent BioSolutions all-time high quarterly selling, general & administrative expenses is $101.30 M
What is Emergent BioSolutions quarterly SG&A year-on-year change?
Over the past year, EBS quarterly selling, general & administrative expenses has changed by -$9.40 M (-10.93%)
What is Emergent BioSolutions TTM selling, general & administrative expenses?
The current TTM SG&A of EBS is -$511.60 M
What is the all time high TTM SG&A for Emergent BioSolutions?
Emergent BioSolutions all-time high TTM selling, general & administrative expenses is $372.10 M
What is Emergent BioSolutions TTM SG&A year-on-year change?
Over the past year, EBS TTM selling, general & administrative expenses has changed by -$883.70 M (-237.49%)